Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-12 transaction · row 30
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
24 source rowsRow 7 · 2026-08-10 · Sale · Disposed 67 · Balance 240,743 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 8 · 2026-08-10 · Sale · Disposed 2,813 · Balance 237,930 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 9 · 2026-08-10 · Sale · Disposed 3,673 · Balance 234,257 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 10 · 2026-08-10 · Sale · Disposed 6,717 · Balance 227,540 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 11 · 2026-08-10 · Sale · Disposed 3,476 · Balance 224,064 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 12 · 2026-08-10 · Sale · Disposed 12,418 · Balance 211,646 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 13 · 2026-08-10 · Sale · Disposed 15,869 · Balance 195,777 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 14 · 2026-08-10 · Sale · Disposed 45,044 · Balance 150,733 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 15 · 2026-08-10 · Sale · Disposed 21,254 · Balance 129,479 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 16 · 2026-08-10 · Sale · Disposed 3,680 · Balance 125,799 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 17 · 2026-08-11 · Sale · Disposed 13,695 · Balance 112,104 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 18 · 2026-08-11 · Sale · Disposed 8,081 · Balance 104,023 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 19 · 2026-08-11 · Sale · Disposed 14,569 · Balance 89,454 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 20 · 2026-08-11 · Sale · Disposed 11,568 · Balance 77,886 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 21 · 2026-08-11 · Sale · Disposed 13,403 · Balance 64,483 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 22 · 2026-08-11 · Sale · Disposed 5,211 · Balance 59,272 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 23 · 2026-08-11 · Sale · Disposed 3,176 · Balance 56,096 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 24 · 2026-08-11 · Sale · Disposed 1,200 · Balance 54,896 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 25 · 2026-08-11 · Sale · Disposed 4 · Balance 54,892 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 26 · 2026-08-12 · Sale · Disposed 1,980 · Balance 52,912 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 27 · 2026-08-12 · Sale · Disposed 2,515 · Balance 50,397 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 28 · 2026-08-12 · Sale · Disposed 15,396 · Balance 35,001 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 29 · 2026-08-12 · Sale · Disposed 20,899 · Balance 14,102 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 30 · 2026-08-12 · Sale · Disposed 14,102 · Balance 0 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,330,988 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,330,988 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 481,533 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 481,533 F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 7,699,158 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,699,158 F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,204,115 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,204,115 F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 9,545,000 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 9,545,000 F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 102,188 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 102,188 F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
F6: Each American Depositary Share represents 13 Ordinary Shares.
F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 1,007,578 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · derivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,559,391 Underlying: Ordinary Shares · 1,007,578 shares Expires 2025-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $264.27 | $26,427.00 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,700 | $262.97 | $447,046.96 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.81 to $263.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,400 | $262.03 | $890,899.96 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.56 to $262.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,906 | $261.08 | $758,696.74 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,200 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.50 to $261.45, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,705 | $259.77 | $1,741,786.01 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,106 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.44 to $260.43, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,200 | $258.91 | $2,123,073.48 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,811 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.44 to $259.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 13,598 | $257.92 | $3,507,198.88 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,011 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.41 to $258.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,500 | $256.91 | $899,199.70 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,609 F7 · security: Each American Depositary Share represents 13 Ordinary Shares F8 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.28 to $257.19, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 40,109 | $6.50 | $260,708.50 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Each American Depositary Share represents 13 Ordinary Shares Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionOrdinary Shares | 486,161 | $0.50 | $243,080.50 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,892,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:26 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 201,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000047 · wk-form4_1741393557.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,405,895 F1 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 2,533,531 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · derivative · entry 20 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,566,969 Underlying: Ordinary Shares · 2,533,531 shares Expires 2025-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 600 | $249.25 | $149,549.04 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.10 to $249.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,900 | $248.63 | $969,670.65 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.09 to $249.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,480 | $247.63 | $1,604,610.65 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.09 to $248.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,243 | $246.57 | $1,785,905.06 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,980 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.08 to $247.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 19,232 | $245.51 | $4,721,706.02 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,223 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.05 to $246.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,090 | $245.36 | $267,437.39 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,455 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.25 to $245.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 18,386 | $244.56 | $4,496,441.55 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,545 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.05 to $245.04, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,910 | $244.45 | $1,200,272.09 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,931 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.17 to $245.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 11,195 | $243.44 | $2,725,326.47 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,841 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.025 to $244.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,192 | $242.46 | $1,986,233.14 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,036 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.9422, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 13,816 | $241.38 | $3,334,881.21 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,228 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.00 to $241.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,956 | $240.53 | $1,432,605.02 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,044 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised. The expiration date of the share option is July 19, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 101,000 | $6.50 | $656,500.00 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each American Depositary Share represents 13 Ordinary Shares Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionOrdinary Shares | 1,220,531 | $0.50 | $610,265.50 |
DisclosureSEC source: 0001651308-25-000039 · wk-form4_1741211959.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,199,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 22:02 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 1,300,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001651308-24-000167 · wk-form4_1734472956.xml · derivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100,500 Underlying: Ordinary Shares · 1,300,000 shares Expires 2025-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 22:02 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionOrdinary Shares | 1,300,000 | $0.50 | $650,000.00 |
DisclosureSEC source: 0001651308-24-000167 · wk-form4_1734472956.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,978,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person exercised and held these option shares. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,452 | $236.37 | $343,208.51 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 20 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.22 to $236.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,059 | $235.41 | $484,714.96 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 1,452 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.01 to $235.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 694 | $234.27 | $162,585.25 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,511 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.00 to $234.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 62 | $233.00 | $14,446.00 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 4,205 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 371 | $231.04 | $85,717.66 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 4,267 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.00 to $231.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,827 | $230.05 | $650,349.94 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 4,638 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.00 to $230.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,535 | $229.25 | $581,139.12 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 7,465 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.00 to $229.49, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 896 | $236.37 | $211,787.07 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.22 to $236.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,272 | $235.41 | $299,445.08 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 896 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.01 to $235.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 428 | $234.27 | $100,268.76 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,168 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.00 to $234.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 38 | $233.00 | $8,854.00 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,596 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 229 | $231.05 | $52,909.35 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,634 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.00 to $231.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,747 | $230.05 | $401,896.65 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,863 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.00 to $230.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,565 | $229.25 | $358,769.83 |
DisclosureSEC source: 0001651308-24-000132 · wk-form4_1728596893.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,610 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.00 to $229.49, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:22 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 400 | $160.12 | $64,049.48 |
DisclosureSEC source: 0001651308-24-000076 · wk-form4_1719436954.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.0149 to $160.16, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:22 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,389 | $159.49 | $381,020.18 |
DisclosureSEC source: 0001651308-24-000076 · wk-form4_1719436954.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.01 to $159.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:27 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 376 | $159.91 | $60,126.65 |
DisclosureSEC source: 0001651308-24-000075 · wk-form4_1718918821.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.40 to $160.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:27 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 608 | $159.40 | $96,914.23 |
DisclosureSEC source: 0001651308-24-000075 · wk-form4_1718918821.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.12 to $159.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:27 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 297 | $158.53 | $47,083.68 |
DisclosureSEC source: 0001651308-24-000075 · wk-form4_1718918821.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 984 F6 · security: Each American Depositary Share represents 13 Ordinary Shares F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 923,975 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000061 · wk-form4_1717793920.xml · derivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,975 Underlying: Ordinary Shares · 923,975 shares Expires 2034-06-04 F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F7 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 490,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000061 · wk-form4_1717793920.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,812,018 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.